Benlysta (belimumab) prior authorization
Customize your policy alerts
Sign up for all Alaska Medicaid policy alerts
Know when Alaska Medicaid releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization criteria for Benlysta (belimumab) for treatment of systemic lupus erythematosus and lupus nephritis for Alaska Medicaid members, including age, diagnosis, prescriber, therapy, and dosing constraints.
No material clinical or coverage changes in this revision.
Coverage Criteria for Benlysta (belimumab)
Initial coverage criteria — Systemic Lupus Erythematosus
Covered when ALL of the following are met for systemic lupus erythematosus
Initial coverage criteria — Lupus Nephritis
Covered when ALL of the following are met for lupus nephritis
The policy specifies several usage constraints for Benlysta. The drug has not been studied in combination with other biologic agents, and its use concurrently with other biologics is not recommended. For dosing route limits, subcutaneous dosing is not approved for patients younger than 18 years of age. The FDA-labeled indications note that Benlysta is indicated for patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard therapy and for adult patients with active lupus nephritis receiving standard therapy; however, the subcutaneous formulation has age-specific approval constraints as stated above. Finally, the clinical program and trials do not provide efficacy data for patients with severe active central nervous system (CNS) lupus, and such scenarios are explicitly excluded from evaluation.
Requests for Benlysta will be considered not medically necessary when the listed approval criteria are not met. In addition, requests will be denied if the patient is taking a concomitant biologic DMARD or Lupkynis, or if the patient has severe active central nervous system lupus.
Provider Requirements and Authorization Steps
Prior authorization required; approvals tied to age, diagnosis, prescriber, antibody status, and therapy
Benlysta (belimumab) requires prior authorization. Approval is only granted when the patient meets the listed age and administration route, has the specified diagnosis, the drug is prescribed by or in consultation with an appropriate specialist, and (for SLE) the patient is autoantibody‑positive. For both SLE and lupus nephritis, the patient must be currently receiving standard immunosuppressive therapy or have a documented contraindication to standard therapy.
- Age and route: ages 5–17 must receive IV; age ≥18 may receive IV or subcutaneous (SLE and lupus nephritis).
- Diagnoses: systemic lupus erythematosus (SLE) or lupus nephritis as specified in criteria.
- Prescriber: prescribed by or in consultation with an appropriate specialist (see documentation requirements).
- SLE-specific: autoantibody‑positive SLE required (positive ANA and/or anti‑dsDNA).
- Therapy: must be currently receiving standard immunosuppressive therapy or have a contraindication.
Standard immunosuppressive therapy required or documented contraindication
Authorization requires the patient to be currently receiving standard immunosuppressive therapy appropriate to the indication, or to have a documented contraindication or intolerance to such therapy.
- For SLE: examples include hydroxychloroquine, chloroquine, prednisone, azathioprine, or methotrexate.
- For lupus nephritis: examples include azathioprine, mycophenolate mofetil, or cyclophosphamide.
Required documentation: prescriber specialty, diagnosis confirmation, antibody status, and therapy details
Submit documentation demonstrating prescriber specialty, confirmed diagnosis, and supporting clinical information at time of prior authorization request.
- Prescriber specialty: rheumatologist, immunologist, nephrologist, neurologist, or dermatologist for SLE; nephrologist or rheumatologist for lupus nephritis (prescription or consultation).
- Diagnosis evidence: for lupus nephritis, ISN/RPS biopsy‑proven active Class III or IV (alone or with Class V); for SLE, documentation of diagnosis.
- Autoantibody evidence: positive ANA and/or anti‑dsDNA for autoantibody‑positive SLE.
- Therapy evidence: documentation of current standard immunosuppressive therapy or a documented contraindication/intolerance.
- Quantity/dosing: supply dosing schedule consistent with IV (10 mg/kg induction then every 4 weeks) or subcutaneous vial/syringe guidance as applicable; HCPCS J0490 for billing.
Denial triggers: unmet criteria, concomitant biologics/Lupkynis, or severe active CNS lupus
Prior authorization will be denied if the approval criteria are not met or if disallowed concomitant therapies or exclusions apply.
- Denial if failure to meet any approval criterion.
- Denial if the patient is taking a concomitant biologic DMARD or Lupkynis.
- Denial if the patient has severe active central nervous system lupus.
Billing Codes and Dosing Examples
| J0490 | Benlysta (belimumab) HCPCS code as listed |
Definitions and Diagnostic Criteria
Background
Benlysta (belimumab) is a BLyS-specific inhibitor indicated for the treatment of patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus who are receiving standard therapy, and for adult patients with active lupus nephritis who are receiving standard therapy. The efficacy of Benlysta has not been evaluated in patients with severe active central nervous system lupus, and it has not been studied in combination with other biologics. Note that subcutaneous dosing is not approved for patients under 18 years of age.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.